# Evaluate the Immunogenicity of a Novel Glucagon Formulation

> **NCT01959334** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 75 (actual)

## Conditions studied

- Drug-specific Antibodies
- Diabetes Mellitus

## Interventions

- **DRUG:** Nasal Glucagon (NG)
- **DRUG:** Glucagon IM

## Key facts

- **NCT ID:** NCT01959334
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959334, "Evaluate the Immunogenicity of a Novel Glucagon Formulation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01959334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*